These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34885245)

  • 41. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
    Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
    Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
    Chu E; Wu J; Kang SS; Kang Y
    Curr Oncol; 2023 Aug; 30(9):7891-7903. PubMed ID: 37754488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma.
    Lejeune M; Köse MC; Jassin M; Gou MJ; Herbet A; Duray E; Cobraiville G; Foguenne J; Boquet D; Gothot A; Beguin Y; Fillet M; Caers J
    Hemasphere; 2023 Jul; 7(7):e901. PubMed ID: 37359190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.
    Nishihori T; Hoffman JE; Huff A; Kapoor GS; Eleftheriadou I; Zajic S; Urbano A; Suchindran S; Chisamore M; D'Souza JW; Faitg T; Rapoport AP
    Blood Adv; 2023 Apr; 7(7):1168-1177. PubMed ID: 36534160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis.
    Wang SH; Chou WC; Huang HC; Lee TA; Hsiao TC; Wang LH; Huang KB; Kuo CT; Chao CH; Chang SJ; Hsu JM; Weng J; Ren N; Li FA; Lai YJ; Zhou C; Hung MC; Li CW
    Am J Cancer Res; 2022; 12(10):4721-4736. PubMed ID: 36381324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model.
    Sokolowska O; Rodziewicz-Lurzynska A; Pilch Z; Kedzierska H; Chlebowska-Tuz J; Sosnowska A; Szumera-Cieckiewicz A; Sokol K; Barankiewicz J; Salomon-Perzynski A; Ciepiela O; Lech-Maranda E; Golab J; Nowis D
    Clin Exp Med; 2023 Sep; 23(5):1563-1572. PubMed ID: 36044158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
    Morabito F; Zamagni E; Conticello C; Pavone V; Palmieri S; Bringhen S; Galli M; Mangiacavalli S; Derudas D; Rossi E; Ria R; Catalano L; Tacchetti P; Mele G; Vincelli ID; Martino EA; Vigna E; Bruzzese A; Mendicino F; Botta C; Mele A; Pantani L; Rocchi S; Garibaldi B; Cascavilla N; Ballanti S; Tripepi G; Frigeri F; Falcone AP; Cangialosi C; Reddiconto G; Farina G; Barone M; Rizzello I; Iaccino E; Mimmi S; Curci P; Gamberi B; Musto P; De Stefano V; Musso M; Petrucci MT; Offidani M; Di Raimondo F; Boccadoro M; Cavo M; Neri A; Gentile M
    Front Oncol; 2022; 12():890376. PubMed ID: 35924160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiotheranostic Agents in Hematological Malignancies.
    Caers J; Duray E; Vrancken L; Marcion G; Bocuzzi V; De Veirman K; Krasniqi A; Lejeune M; Withofs N; Devoogdt N; Dumoulin M; Karlström AE; D'Huyvetter M
    Front Immunol; 2022; 13():911080. PubMed ID: 35865548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune-based therapies in penile cancer.
    Joshi VB; Spiess PE; Necchi A; Pettaway CA; Chahoud J
    Nat Rev Urol; 2022 Aug; 19(8):457-474. PubMed ID: 35851333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.
    Huo J; Huang Y; Zheng Z; Tay XN; Mahfut FB; Zhang W; Lam KP; Yang Y; Xu S
    Antib Ther; 2022 Apr; 5(2):138-149. PubMed ID: 35774245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.
    Kumar S; Baizer L; Callander NS; Giralt SA; Hillengass J; Freidlin B; Hoering A; Richardson PG; Schwartz EI; Reiman A; Lentzsch S; McCarthy PL; Jagannath S; Yee AJ; Little RF; Raje NS
    Blood Cancer J; 2022 Jun; 12(6):98. PubMed ID: 35768410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies.
    Martelli AM; Paganelli F; Evangelisti C; Chiarini F; McCubrey JA
    Cells; 2022 May; 11(11):. PubMed ID: 35681507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in the treatment of extramedullary disease in multiple myeloma.
    Li Y; Sun Z; Qu X
    Transl Oncol; 2022 Aug; 22():101465. PubMed ID: 35679743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.
    Desantis V; Savino FD; Scaringella A; Potenza MA; Nacci C; Frassanito MA; Vacca A; Montagnani M
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.
    Venditto VJ; Feola DJ
    Adv Drug Deliv Rev; 2022 May; 184():114252. PubMed ID: 35367307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.
    Reina-Ortiz C; Giraldos D; Azaceta G; Palomera L; Marzo I; Naval J; Villalba M; Anel A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
    Cho SF; Xing L; Anderson KC; Tai YT
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
    Cho SF; Lin L; Xing L; Li Y; Yu T; Anderson KC; Tai YT
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
    Xia J; Li Z; Xu K
    J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.